Wide Ranks

AKYA

Akoya BioSciences, Inc.

2.14

Top Statistics
Market Cap 106 M Forward PE -3.43 Revenue Growth -1.50 %
Current Ratio 2.73 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -64.74 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.92 Enterprise / Revenue 2.09 Price To Sales Trailing12 Months 1.14
Profitability
Profit Margins -64.74 % Operating Margins -47.47 %
Balance Sheet
Total Cash 45 M Total Cash Per Share 0.9140 Total Debt 84 M
Total Debt To Equity 380.68 Current Ratio 2.73 Book Value Per Share 1.09
All Measures
Short Ratio 1343.00 % Message Board Id finmb_530456307 Fax 855 404 0061
Shares Short Prior Month 2 M Return On Equity -1.28 City Marlborough
Uuid eb3df861-adbf-3878-b6cb-be19fbedde1b Previous Close 2.20 First Trade Date Epoch Utc 1 B
Book Value 1.09 Beta 1.35 Total Debt 84 M
Volume 135023 Price To Book 1.95 Fifty Two Week Low 1.88
Total Cash Per Share 0.9140 Total Revenue 93 M Shares Short Previous Month Date 1 B
Target Median Price 3.00 Audit Risk 4 Max Age 86400
Recommendation Mean 2.38 Sand P52 Week Change 0.3133 Operating Margins -47.47 %
Target Mean Price 3.50 Net Income To Common -60351000 Short Percent Of Float 0.0534
Implied Shares Outstanding 49 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 293040 Average Volume10days 293040 Total Cash 45 M
Next Fiscal Year End 1 B Revenue Per Share 1.89 Held Percent Insiders 0.1109
Ebitda Margins -42.36 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 2.20
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.81
Open 2.26 Free Cashflow -34914376 State MA
Dividend Yield 0.00 % Return On Assets -0.1809 Time Zone Short Name EST
Board Risk 8 Trailing Eps -1.16 Day Low 2.11
Address1 100 Campus Drive Shares Outstanding 49 M Compensation Risk 9
Price Hint 4 Target High Price 5.00 Website https://www.akoyabio.com
52 Week Change -0.5125 Average Volume 154675 Forward Eps -0.5500
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 188.70 %
Is_sp_500 False Regular Market Day High 2.26 Profit Margins -64.74 %
Debt To Equity 380.68 Fifty Two Week High 6.31 Day High 2.26
Shares Short 1 M Regular Market Open 2.26 Industry Key medical-instruments-supplies
Earnings Growth 0.00 % Enterprise To Revenue 2.09 Revenue Growth -1.50 %
Shares Percent Shares Out 0.0324 Operating Cashflow -51202000 Currency USD
Time Zone Full Name America/New_York Market Cap 106 M Is_nasdaq_100 False
Zip 01752 Quote Type EQUITY Industry Medical Instruments & Supplies
Long Name Akoya Biosciences, Inc. Overall Risk 8 Regular Market Day Low 2.11
Held Percent Institutions 0.7019 Current Price 2.14 Address2 6th Floor
Enterprise To Ebitda -4.92 Financial Currency USD Current Ratio 2.73
Gross Margins 57.57 % Industry Disp Medical Instruments & Supplies Number Of Analyst Opinions 5
Country United States Float Shares 16 M Two Hundred Day Average 3.18
Governance Epoch Date 1 B Enterprise Value 194 M Price To Sales Trailing12 Months 1.14
Forward PE -3.43 Regular Market Volume 135023 Ebitda -39486000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.

The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

It also provides PhenoCycler and PhenoImager reagents; and biopharma services.

In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.

It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients.

The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.